# Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

> **NCT03977480** · PHASE2 · TERMINATED · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 70 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Hemay007
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03977480
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-13
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-08-12
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Due to the difficulty to recruit enough patients, the study was terminated.
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03977480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03977480, "Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03977480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*